Drugs / STSA-1201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05986877 | Aug 2023 → Mar 2024 | — | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STSA-1201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05986877 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT05986877 ↗ |